Compare SKY & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKY | OABI |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 237.4M |
| IPO Year | 1994 | N/A |
| Metric | SKY | OABI |
|---|---|---|
| Price | $69.30 | $1.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $98.50 | $4.50 |
| AVG Volume (30 Days) | 403.3K | ★ 657.9K |
| Earning Date | 05-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.18 | N/A |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $2,483,448,000.00 | N/A |
| Revenue This Year | $7.79 | $52.42 |
| Revenue Next Year | $3.10 | $64.69 |
| P/E Ratio | $22.11 | ★ N/A |
| Revenue Growth | ★ 22.65 | N/A |
| 52 Week Low | $59.44 | $1.22 |
| 52 Week High | $99.17 | $2.22 |
| Indicator | SKY | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 71.86 |
| Support Level | $64.07 | $1.83 |
| Resistance Level | $79.44 | $1.89 |
| Average True Range (ATR) | 2.86 | 0.09 |
| MACD | -0.88 | 0.05 |
| Stochastic Oscillator | 11.21 | 93.52 |
Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business with 72 retail locations across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several dispatch locations across the United States.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.